Why SpaceX (SPCX) rose 16.43%
SpaceX (SPCX) rose 16.43% on August 8, 2026 — Q2 revenue beat + lockup relief lifts SpaceX.
What happened
SpaceX reported Q2 revenue that beat expectations, paired with lockup relief (share-sale restrictions easing) and a major update on Terafab, its Texas-based chip manufacturing facility.
Why it moved
Revenue beats expand visible cash generation and growth trajectory; lockup relief reduces overhang risk and can unlock secondary-market demand as insiders gain liquidity optionality.
Why it matters
SpaceX sits at the nexus of the Space & Defense supercycle — a theme spanning satellite broadband, government contracts, and now advanced manufacturing (Terafab).
What would break the thesis
If Terafab fails to meet production milestones, regulatory delays surface, or lockup supply floods secondary markets faster than demand absorbs it, the valuation re-rating can reverse sharply.